A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.

Trial Profile

A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs Ublituximab (Primary) ; Umbralisib (Primary) ; Bendamustine; Ibrutinib
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 26 Jun 2017 Results published in a TG Therapeutics media release.
    • 26 Jun 2017 According to a TG Therapeutics media release, data from this trial was presented at the 22nd European Hematology Association (EHA) Annual Congress
    • 25 Jun 2017 Results (n=38) presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top